References
1. Rankin A, Cadogan CA, Patterson SM, Kerse N, Cardwell CR, Bradley MC,
Ryan C, Hughes C: Interventions to improve the appropriate use of
polypharmacy for older people. Cochrane Database Syst Rev 2018,
9:CD008165.
2. Gutierrez-Valencia M, Izquierdo M, Cesari M, Casas-Herrero A,
Inzitari M, Martinez-Velilla N: The relationship between frailty and
polypharmacy in older people: A systematic review. Br J Clin
Pharmacol 2018, 84(7):1432-1444.
3. Fried TR, O’Leary J, Towle V, Goldstein MK, Trentalange M, Martin DK:
Health outcomes associated with polypharmacy in community-dwelling older
adults: a systematic review. J Am Geriatr Soc 2014,
62(12):2261-2272.
4. Cahir C, Fahey T, Teeling M, Teljeur C, Feely J, Bennett K:
Potentially inappropriate prescribing and cost outcomes for older
people: a national population study. Br J Clin Pharmacol 2010,
69(5):543-552.
5. Motter FR, Fritzen JS, Hilmer SN, Paniz EV, Paniz VMV: Potentially
inappropriate medication in the elderly: a systematic review of
validated explicit criteria. Eur J Clin Pharmacol 2018,
74(6):679-700.
6. Storms H, Marquet K, Aertgeerts B, Claes N: Prevalence of
inappropriate medication use in residential long-term care facilities
for the elderly: A systematic review. Eur J Gen Pract 2017,
23(1):69-77.
7. O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P:
STOPP/START criteria for potentially inappropriate prescribing in older
people: version 2. Age Ageing 2015, 44(2):213-218.
8. By the American Geriatrics Society Beers Criteria Update Expert P:
American Geriatrics Society 2015 Updated Beers Criteria for Potentially
Inappropriate Medication Use in Older Adults. J Am Geriatr Soc2015, 63(11):2227-2246.
9. Hanlon JT, Schmader KE, Samsa GP, Weinberger M, Uttech KM, Lewis IK,
Cohen HJ, Feussner JR: A method for assessing drug therapy
appropriateness. J Clin Epidemiol 1992, 45(10):1045-1051.
10. Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML,
Extermann M, Falandry C, Artz A, Brain E, Colloca G et al :
International Society of Geriatric Oncology consensus on geriatric
assessment in older patients with cancer. J Clin Oncol 2014,
32(24):2595-2603.
11. Mohamed MR, Ramsdale E, Loh KP, Arastu A, Xu H, Obrecht S, Castillo
D, Sharma M, Holmes HM, Nightingale G et al : Associations of
Polypharmacy and Inappropriate Medications with Adverse Outcomes in
Older Adults with Cancer: A Systematic Review and Meta-Analysis.Oncologist 2020, 25(1):e94-e108.
12. Maggiore RJ, Gross CP, Hurria A: Polypharmacy in older adults with
cancer. Oncologist 2010, 15(5):507-522.
13. Sharma M, Loh KP, Nightingale G, Mohile SG, Holmes HM: Polypharmacy
and potentially inappropriate medication use in geriatric oncology.J Geriatr Oncol 2016, 7(5):346-353.
14. LeBlanc TW, McNeil MJ, Kamal AH, Currow DC, Abernethy AP:
Polypharmacy in patients with advanced cancer and the role of medication
discontinuation. Lancet Oncol 2015, 16(7):e333-341.
15. Lees J, Chan A: Polypharmacy in elderly patients with cancer:
clinical implications and management. Lancet Oncol 2011,
12(13):1249-1257.
16. Oldak S, Ioannou S, Kamath P, Huang M, George S, Slomovitz B,
Schlumbrecht M: Polypharmacy in Patients with Ovarian Cancer.Oncologist 2019, 24(9):1201-1208.
17. Hong S, Lee JH, Chun EK, Kim KI, Kim JW, Kim SH, Lee YG, Hwang IG,
Kim JY, Koh SJ et al : Polypharmacy, Inappropriate Medication Use,
and Drug Interactions in Older Korean Patients with Cancer Receiving
First-Line Palliative Chemotherapy. Oncologist 2019.
18. Calip GS, Xing S, Jun DH, Lee WJ, Hoskins KF, Ko NY: Polypharmacy
and Adherence to Adjuvant Endocrine Therapy for Breast Cancer. J
Oncol Pract 2017, 13(5):e451-e462.
19. Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H,
Japan Cancer Surveillance Research G: Cancer incidence and incidence
rates in Japan in 2008: a study of 25 population-based cancer registries
for the Monitoring of Cancer Incidence in Japan (MCIJ) project.Jpn J Clin Oncol 2014, 44(4):388-396.
20. Little AG, Gay EG, Gaspar LE, Stewart AK: National survey of
non-small cell lung cancer in the United States: epidemiology, pathology
and patterns of care. Lung Cancer 2007, 57(3):253-260.
21. Health USNIo: SEER Cancer Stat Facts.
22. Tamura T, Kurishima K, Nakazawa K, Kagohashi K, Ishikawa H, Satoh H,
Hizawa N: Specific organ metastases and survival in metastatic
non-small-cell lung cancer. Mol Clin Oncol 2015, 3(1):217-221.
23. Salz T, Lavery JA, Lipitz-Snyderman AN, Boudreau DM, Moryl N,
Gillespie EF, Korenstein D: Trends in Opioid Use Among Older Survivors
of Colorectal, Lung, and Breast Cancers. J Clin Oncol 2019,
37(12):1001-1011.
24. Hasegawa T, Oguri T, Osawa T, Sawa T, Osaga S, Okuyama T, Uchida M,
Maeno K, Fukuda S, Nishie H et al : Opioid Dose and Survival of
Patients with Incurable Nonsmall Cell Lung Cancer: A Prospective Cohort
Study. J Palliat Med 2018, 21(10):1436-1441.
25. Sutradhar R, Lokku A, Barbera L: Cancer survivorship and opioid
prescribing rates: A population-based matched cohort study among
individuals with and without a history of cancer. Cancer 2017,
123(21):4286-4293.
26. Vora N, Reckamp KL: Non-small cell lung cancer in the elderly:
defining treatment options. Semin Oncol 2008, 35(6):590-596.
27. Todd A, Williamson S, Husband A, Baqir W, Mahony M: Patients with
advanced lung cancer: is there scope to discontinue inappropriate
medication? Int J Clin Pharm 2013, 35(2):181-184.
28. Bigot F, Castanon E, Baldini C, Hollebecque A, Carmona A,
Postel-Vinay S, Angevin E, Armand JP, Ribrag V, Aspeslagh S et
al : Prospective validation of a prognostic score for patients in
immunotherapy phase I trials: The Gustave Roussy Immune Score
(GRIm-Score). Eur J Cancer 2017, 84:212-218.
29. Rami-Porta R, Bolejack V, Crowley J, Ball D, Kim J, Lyons G, Rice T,
Suzuki K, Thomas CF, Jr., Travis WD et al : The IASLC Lung Cancer
Staging Project: Proposals for the Revisions of the T Descriptors in the
Forthcoming Eighth Edition of the TNM Classification for Lung Cancer.J Thorac Oncol 2015, 10(7):990-1003.
30. Feuth T: [The start of 2 levels of competence–from the
viewpoint of professional content and organization]. TVZ1992(10):371-375.
31. Vishwanathan K, Dickinson PA, So K, Thomas K, Chen YM, De Castro
Carpeno J, Dingemans AC, Kim HR, Kim JH, Krebs MG et al : The
effect of itraconazole and rifampicin on the pharmacokinetics of
osimertinib. Br J Clin Pharmacol 2018, 84(6):1156-1169.
32. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R: FDA drug
approval summary: erlotinib (Tarceva) tablets. Oncologist 2005,
10(7):461-466.
33. Wind S, Schnell D, Ebner T, Freiwald M, Stopfer P: Clinical
Pharmacokinetics and Pharmacodynamics of Afatinib. Clin
Pharmacokinet 2017, 56(3):235-250.
34. Maggiore RJ, Dale W, Gross CP, Feng T, Tew WP, Mohile SG, Owusu C,
Klepin HD, Lichtman SM, Gajra A et al : Polypharmacy and
potentially inappropriate medication use in older adults with cancer
undergoing chemotherapy: effect on chemotherapy-related toxicity and
hospitalization during treatment. J Am Geriatr Soc 2014,
62(8):1505-1512.
35. Park JW, Roh JL, Lee SW, Kim SB, Choi SH, Nam SY, Kim SY: Effect of
polypharmacy and potentially inappropriate medications on treatment and
posttreatment courses in elderly patients with head and neck cancer.J Cancer Res Clin Oncol 2016, 142(5):1031-1040.
36. Raijmakers NJ, van Zuylen L, Furst CJ, Beccaro M, Maiorana L,
Pilastri P, Rossi C, Flego G, van der Heide A, Costantini M: Variation
in medication use in cancer patients at the end of life: a
cross-sectional analysis. Support Care Cancer 2013,
21(4):1003-1011.
37. Sasaki T, Fujita K, Sunakawa Y, Ishida H, Yamashita K, Miwa K, Saji
S, Kato Y, Sasaki Y: Concomitant polypharmacy is associated with
irinotecan-related adverse drug reactions in patients with cancer.Int J Clin Oncol 2013, 18(4):735-742.
38. Iurlo A, Nobili A, Latagliata R, Bucelli C, Castagnetti F, Breccia
M, Abruzzese E, Cattaneo D, Fava C, Ferrero D et al : Imatinib and
polypharmacy in very old patients with chronic myeloid leukemia: effects
on response rate, toxicity and outcome. Oncotarget 2016,
7(48):80083-80090.
39. Kotlinska-Lemieszek A, Paulsen O, Kaasa S, Klepstad P: Polypharmacy
in patients with advanced cancer and pain: a European cross-sectional
study of 2282 patients. J Pain Symptom Manage 2014,
48(6):1145-1159.
40. Cashman J, Wright J, Ring A: The treatment of co-morbidities in
older patients with metastatic cancer. Support Care Cancer 2010,
18(5):651-655.
41. Bjerrum L, Rosholm JU, Hallas J, Kragstrup J: Methods for estimating
the occurrence of polypharmacy by means of a prescription database.Eur J Clin Pharmacol 1997, 53(1):7-11.
42. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of
classifying prognostic comorbidity in longitudinal studies: development
and validation. J Chronic Dis 1987, 40(5):373-383.
43. Charlson M, Szatrowski TP, Peterson J, Gold J: Validation of a
combined comorbidity index. J Clin Epidemiol 1994,
47(11):1245-1251.
44. Elixhauser A, Steiner C, Harris DR, Coffey RM: Comorbidity measures
for use with administrative data. Med Care 1998, 36(1):8-27.
45. Freyer G, Geay JF, Touzet S, Provencal J, Weber B, Jacquin JP, Ganem
G, Tubiana-Mathieu N, Gisserot O, Pujade-Lauraine E: Comprehensive
geriatric assessment predicts tolerance to chemotherapy and survival in
elderly patients with advanced ovarian carcinoma: a GINECO study.Ann Oncol 2005, 16(11):1795-1800.
46. Elliot K, Tooze JA, Geller R, Powell BL, Pardee TS, Ritchie E,
Kennedy L, Callahan KE, Klepin HD: The prognostic importance of
polypharmacy in older adults treated for acute myelogenous leukemia
(AML). Leuk Res 2014, 38(10):1184-1190.
47. Page RL, 2nd, Linnebur SA, Bryant LL, Ruscin JM: Inappropriate
prescribing in the hospitalized elderly patient: defining the problem,
evaluation tools, and possible solutions. Clin Interv Aging 2010,
5:75-87.
48. Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A,
Takahashi K, Fujita Y, Harada T, Minato K et al : Gefitinib Alone
Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With
Mutated Epidermal Growth Factor Receptor: NEJ009 Study. J Clin
Oncol 2020, 38(2):115-123.
49. Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S,
Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K et al : Erlotinib
plus bevacizumab versus erlotinib alone in patients with EGFR-positive
advanced non-squamous non-small-cell lung cancer (NEJ026): interim
analysis of an open-label, randomised, multicentre, phase 3 trial.Lancet Oncol 2019, 20(5):625-635.
50. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D,
Nogami N, Rodriguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi Fet al : Atezolizumab for First-Line Treatment of Metastatic
Nonsquamous NSCLC. N Engl J Med 2018, 378(24):2288-2301.
51. Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y,
Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B et al :
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced
NSCLC. N Engl J Med 2020, 382(1):41-50.
52. Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd
FA, He Y, Akamatsu H, Theelen WS et al : Osimertinib or
Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J
Med 2017, 376(7):629-640.